Revvity (RVTY) has announced that its Signals AI software has joined Anthropic's Model Context Protocol connector directory. The stock is currently trading at $111.11, with a 30-day return of 11.49% and a 90-day return of 18.82%.
TL;DR
- Revvity's Signals AI software now integrates with Anthropic's Claude and Claude Science.
- The stock has seen significant gains but still trades below some fair value estimates.
- Investors should consider both the opportunities and risks, including regulatory pressures and potential demand softness.
What happened
Revvity's Signals AI software has been added to Anthropic's Model Context Protocol connector directory, enabling integration with Claude and Claude Science for scientific research workflows. This partnership comes as Revvity's stock is trading at $111.11, with notable gains over the past 30 and 90 days. The company's one-year total shareholder return stands at 13.16%, although this contrasts with weaker returns over three and five years. Despite the recent rally, Revvity's stock still trades below some fair value estimates and analyst targets.
Why it matters
For AI/ML developers, this integration could open up new workflow possibilities, particularly in scientific research, by leveraging the capabilities of both Revvity's Signals AI and Anthropic's Claude models. Startup founders in the AI space may see this as a strategic move that could influence their own partnerships and integrations. Tech investors should note that while Revvity's stock has shown recent gains, it remains below some fair value estimates, presenting a potential opportunity or a sign of market caution. The competitive angle here is the potential for enhanced scientific research capabilities, which could attract more users and investors to both Revvity and Anthropic.
Key facts
- Revvity's stock is currently trading at $111.11.
- The stock has a 30-day return of 11.49% and a 90-day return of 18.82%.
- One-year total shareholder return is 13.16%.
- Revvity's fair value is estimated at $113.64, slightly above the last close.
- The company expects to start 2026 with a 28% operating margin baseline.
- Revvity is shifting its product mix towards higher-margin software and consumables offerings.
- Potential risks include regulatory pressure in key diagnostics markets and softer academic or government demand.
Context
This partnership between Revvity and Anthropic highlights the growing trend of AI integrations in scientific research. As AI models become more sophisticated, the ability to seamlessly integrate different AI tools and platforms is becoming increasingly important. This trend is likely to continue as more companies look to leverage AI for research and development. For investors, this move underscores the potential for AI-driven growth in the healthcare and diagnostics sectors, although it also highlights the need to carefully consider the risks associated with regulatory pressures and market demand.
